➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Moodys
Mallinckrodt
Boehringer Ingelheim
Baxter
McKesson
Merck

Last Updated: September 22, 2020

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR EVACETRAPIB

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

Clinical Trials for Evacetrapib

Trial ID Title Status Sponsor Phase Summary
NCT01687998 A Study of Evacetrapib in High-Risk Vascular Disease Terminated The Cleveland Clinic Phase 3 The purpose of the ACCELERATE study is to evaluate the efficacy and safety of evacetrapib in participants with high-risk vascular disease (HRVD).
NCT01687998 A Study of Evacetrapib in High-Risk Vascular Disease Terminated Eli Lilly and Company Phase 3 The purpose of the ACCELERATE study is to evaluate the efficacy and safety of evacetrapib in participants with high-risk vascular disease (HRVD).
NCT01736254 A Study of Evacetrapib in Healthy Participants Completed Eli Lilly and Company Phase 1 The purpose of this study is to measure how much of the study drug (evacetrapib) gets into the blood stream and how long it takes the body to get rid of it when given with gemfibrozil. Each participant will receive gemfibrozil alone, evacetrapib alone, and both drugs in combination. There is no washout period between doses. The safety of both of the study drugs given together will be evaluated. Information about any side effects that may occur will also be collected. This study will last approximately 36 days.
NCT01746732 A Study of Evacetrapib in Healthy Female Participants Completed Eli Lilly and Company Phase 1 The purpose of this study is to evaluate the effects of evacetrapib on oral contraceptives (Ortho-Cyclen®) when given to healthy female participants. The amount of female hormones found in the blood will be measured and compared when taken alone and when taken with evaceptrapib. Each woman will participate in two study periods. Information about any side effects that may occur will also be collected.
NCT01810432 Study of Food on Evacetrapib (LY2484595) in Healthy Participants Completed Eli Lilly and Company Phase 1 The purpose of this study is to measure how much of the drug gets into the blood stream and how long it takes the body to get rid of it when given to healthy participants. Information about any side effects that may occur will also be collected. The study has 2 periods. In each period, participants will take the study drug for 10 days, either with or without a meal. There is a minimum 14 day washout between each period. This study is approximately 50 days, not including screening. Screening is required within 28 days prior to the start of the study.
>Trial ID >Title >Status >Phase >Summary

Clinical Trial Conditions for Evacetrapib

Condition Name

Condition Name for
Intervention Trials
Healthy Volunteers 12
Hypercholesterolemia 2
Healthy 2
Cardiovascular Diseases 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Condition MeSH

Condition MeSH for
Intervention Trials
Cardiovascular Diseases 2
Hypercholesterolemia 2
Hyperlipidemias 1
Dyslipidemias 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Locations for Evacetrapib

Trials by Country

Trials by Country for
Location Trials
United States 86
United Kingdom 9
Australia 5
Canada 4
Japan 4
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Trials by US State

Trials by US State for
Location Trials
Florida 7
Wisconsin 7
Texas 5
Indiana 3
New Jersey 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Progress for Evacetrapib

Clinical Trial Phase

Clinical Trial Phase for
Clinical Trial Phase Trials
Phase 3 4
Phase 1 17
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Status

Clinical Trial Status for
Clinical Trial Phase Trials
Completed 17
Terminated 4
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Sponsors for Evacetrapib

Sponsor Name

Sponsor Name for
Sponsor Trials
Eli Lilly and Company 21
The Cleveland Clinic 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Sponsor Type

Sponsor Type for
Sponsor Trials
Industry 21
Other 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Medtronic
Merck
Express Scripts
Mallinckrodt
Johnson and Johnson
Colorcon

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.